- Trials with a EudraCT protocol (40)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
40 result(s) found for: Ultrasounds.
Displaying page 1 of 2.
EudraCT Number: 2017-000189-31 | Sponsor Protocol Number: PRI04/2016 | Start Date*: 2017-05-12 |
Sponsor Name:Pannon Reprodukciós Intézet B.1.2 | ||
Full Title: Optimization and Safety Testing of Hormone Normalization Therapy in Advanced Maternal Age Infertile Women | ||
Medical condition: The therapy is intended to treat infertility that is caused by declining egg quality that occurs with advanced maternal age. The purpose of this pilot trial is to optimize the therapeutic protocol.... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: HU (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002919-28 | Sponsor Protocol Number: CORTLATE | Start Date*: 2011-07-12 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO | |||||||||||||
Full Title: Antenatal corticosteroids and respiratory distress syndrome in late preterm infants born by elective cesarean section. Multicentric randomized controlled clinical trial | |||||||||||||
Medical condition: Prophylaxis of respiratory distress syndrome in late preterm infants (34-36 weeks of gestational age)with antenatal corticosteroids | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-003929-27 | Sponsor Protocol Number: STRADIVARIUS | Start Date*: 2005-04-14 |
Sponsor Name:SANOFI-SYNTHELABO | ||
Full Title: Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg od, for inhibition of atherosclerosis progression assessed by IVUS (IntraVascular UltraSo... | ||
Medical condition: Inhibition of coronary atherosclerosis progression in overweight patients with a cluster of risk factors. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000284-21 | Sponsor Protocol Number: 524E-CVD-9101-004 | Start Date*: 2007-11-08 | |||||||||||
Sponsor Name:York Hospitals NHS Foundation Trust [...] | |||||||||||||
Full Title: A multicentre, multinational randomised control trial of prophylactic low molecular weight heparin(LMWH) in high risk pregnant thrombophilic women | |||||||||||||
Medical condition: Thrombophilia in pregnancy. This is a multi-centre, multi-national randomised controlled trial of Low Molecular Weight Heparin to prevent pregnancy complications in high-risk pregnant thrombophi... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014885-25 | Sponsor Protocol Number: CHIC001 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Centre Hospitalier Intercommunal de Créteil | ||||||||||||||||||
Full Title: PRETTINEO PREmedication Trial for Tracheal Intubation of the NEOnate | ||||||||||||||||||
Medical condition: Comparison of two premedication regimens for semi-elective or elective intubation of newborns (term and preterm) hospitalized in the NICU | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-004198-41 | Sponsor Protocol Number: UCDCRC/16/003 | Start Date*: 2017-01-27 | |||||||||||
Sponsor Name:University College Dublin | |||||||||||||
Full Title: PROPHYLACTIC OROPHARYNGEAL SURFACTANT FOR PRETERM INFANTS: A RANDOMISED TRIAL (THE POPART TRIAL) | |||||||||||||
Medical condition: Preterm Infants at risk of respiratory distress syndrome | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) BE (Completed) SE (Completed) CZ (Completed) PT (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000568-41 | Sponsor Protocol Number: GS-US-417-0301 | Start Date*: 2016-10-11 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to ... | |||||||||||||
Medical condition: Moderately to severely active rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) GB (Completed) BE (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BG (Completed) PL (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000028-34 | Sponsor Protocol Number: H3E-MC-JMDB | Start Date*: 2004-07-06 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: A randomised Phase 3 Trial of ALIMTA and Cisplatin versus GEMZAR and Cisplatin in Patients with locally advanced or metastatic Non-Small-Cell Lung Cancer | ||
Medical condition: Locally advanced or metastatic Non-Small Cell Lung Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) FI (Completed) ES (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001056-19 | Sponsor Protocol Number: HUPA-EC-02-2012 | Start Date*: 2013-12-01 | |||||||||||
Sponsor Name:FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS | |||||||||||||
Full Title: ROLE OF BIOLOGICAL THERAPY IN ROTATOR CUFF TENDINOPATHY. EFFECTIVENESS OF PLASMA RICH IN GROWTH FACTOR (PRGF-ENDORET)REGARDING TO FUNCTIONAL CAPACITY AND PAIN COMPARED WITH THE CONVENTIONAL TREATME... | |||||||||||||
Medical condition: ROTATOR CUFF TENDINOPATHY | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000993-32 | Sponsor Protocol Number: S55300 | Start Date*: 2013-05-07 | ||||||||||||||||
Sponsor Name:University Hospital Leuven | ||||||||||||||||||
Full Title: Does prolonged GnRH downregulation prior to ART improve the clinical pregnancy rate in postoperative endometriosis patients? A RCT | ||||||||||||||||||
Medical condition: endometriosis, subfertility | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: BE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000569-21 | Sponsor Protocol Number: GS-US-417-0302 | Start Date*: 2017-01-30 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disea... | |||||||||||||
Medical condition: Moderately to severely active rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) DE (Completed) FR (Completed) HU (Completed) ES (Completed) PL (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004305-40 | Sponsor Protocol Number: CSL222-3001 | Start Date*: 2018-10-12 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene ... | |||||||||||||
Medical condition: Hemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005305-58 | Sponsor Protocol Number: H6Q-MC-S023 | Start Date*: 2007-04-12 | |||||||||||
Sponsor Name:Eli Lilly and Company limited | |||||||||||||
Full Title: A Randomized, Double-Blind, Phase 2 Trial of Fulvestrant Plus Enzastaurin versus Fulvestrant Plus Placebo in Aromatase Inhibitor-Resistant Metastatic Breast Cancer | |||||||||||||
Medical condition: metastatic breast cancer, resistant to aromatase inhibitors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NL (Completed) FR (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004451-37 | Sponsor Protocol Number: C3731003 | Start Date*: 2021-09-24 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Sev... | |||||||||||||
Medical condition: hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Completed) ES (Restarted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011611-21 | Sponsor Protocol Number: H3E-MC-S123 | Start Date*: 2009-11-09 | |||||||||||
Sponsor Name:Eli Lilly and Company Ltd. | |||||||||||||
Full Title: Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | |||||||||||||
Medical condition: Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002818-35 | Sponsor Protocol Number: H3E-SB-S109 | Start Date*: 2007-09-27 |
Sponsor Name:Lilly Deutschland GmbH | ||
Full Title: A Randomized Phase 2 Study of Pemetrexed in Combination with Cisplatin or Carboplatin in the First Line Therapy of Advanced NSCLC | ||
Medical condition: advanced NSCLC of Stage IIIb or IV undergoing first line chemotherapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005696-17 | Sponsor Protocol Number: 1645-CI-058 | Start Date*: 2013-06-18 |
Sponsor Name:Instituto de Investigacion Sanitaria La Fe | ||
Full Title: Multicenter, randomized, blinded clinical study comparing early use of total body moderate hypothermia plus topiramate or placebo in asphyxiated newborn infants evolving to moderate-to-severe hypox... | ||
Medical condition: Asphyxiated newborn infants evolving to moderate-to-severe hypoxic ischemic encephalopathy | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000912-97 | Sponsor Protocol Number: H3E-EW-S115 | Start Date*: 2007-07-26 | |||||||||||
Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
Full Title: Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas | |||||||||||||
Medical condition: Advanced/Metastatic Osteosarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IT (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000691-13 | Sponsor Protocol Number: H3E-MC-JMGV | Start Date*: 2004-11-22 |
Sponsor Name:Lilly S.A. | ||
Full Title: A phase 2 study of ALIMTA plus doxorubicin administered every 21 days in patients with advanced breast cancer | ||
Medical condition: Advanced breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-003011-97 | Sponsor Protocol Number: 69HCL20_0071 | Start Date*: 2020-12-14 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: Fluconazole as a new therapeutic tool in hypercalciuric patients with increased 1,25(OH)2D levels. | |||||||||||||
Medical condition: Hypercalciuria | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
